Clinical Trial

A Study on Ivonescimab Plus Chemotherapy as Neoadjuvant Therapy for Borderline Resectable Pancreatic Cancer

Recruiting Phase 2
View on ClinicalTrials.gov →
Record status
This record was last updated May 31, 2025 (before its estimated April 28, 2026 completion). Its status may not reflect the trial's current state.
Summary
This trial is a prospective, single-arm, single-center Phase II clinical study aimed at evaluating the efficacy and safety of Ivonescimab combined with the gemcitabine and nab-paclitaxel (AG) regimen as neoadjuvant therapy for borderline resectable pancreatic cancer.
Protocol Amendment History 1 amendment
This ClinicalTrials.gov record has been amended once since 2025-04-17.
Trial Details
NCT Number NCT06944106
Lead Sponsor Tianjin Medical University Cancer Institute and Hospital
Conditions Pancreatic Cancer
Enrollment 30 participants
Start Date 2025-03-28
Primary Completion 2026-04-28 (estimated)
Study Completion 2027-03-28 (estimated)
Updated on ClinicalTrials.gov 2025-05-31